DOI: https://dx.doi.org/10.18565/pharmateca.2022.4.87-91
К.Ю. Жеребчикова, А.С. Ермолаева, Ю.П. Сыч, В.В. Фадеев
Первый МГМУ им. И.М. Сеченова (Сеченовский Университет), Москва, Россия
1. Wootla B., Watzlawik J.O., Stavropoulos N., et al. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther 2016;16(6):827-39. Doi: 10.1517/14712598.2016.1158809. 2. Panitch H., Anaissie E., Cines D., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801. Doi: 10.1056/NEJMoa0802670. 3. Cohen J.A., Coles A.J., Arnold D.L., et al. Alemtuzumab versus interferon beta 1a as first- line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-28. Doi: 10.1016/S0140-6736(12)61769-3. 4. Berger T., Elovaara I., Fredrikson S., et al. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS. Drugs. 2017;31(1):33- 50. Doi: 10.1007/s40263-016-0394-8. 5. Baker D., Herrod S.S., Alvarez-Gonzalez C., et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA. Neurol. 2017;74(8):961-69. Doi: 10.1001/jamaneurol.2017.0676. 6. Mahzari M., Arnaout A., Freedman M.S. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management. Can J Neurol Sci. 2015;42(5):284-91. Doi: 10.1017/cjn.2015.48. 7. Antonelli A., Ferrari S.M., Corrado A., et al. Autoimmune thyroid disorders. Autoimmum Rev. 2015;14:174-80. Doi: 10.1016/j. autrev.2014.10.016. 8. Marrie R.A., Reider N., Cohen J., et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2015;21(3):282-93. Doi: 10.1177/1352458514564490 9. Autoimmunity in patients treated With Alemtuzumab for. ECTRIMS Online Library. Vermersch P. 2016 Sep 16; 147015 10. Havrdova E., Arnold D.L., Cohen J.A., et al. On behalf of CARE-MS I and CAMMS03409 Investigators Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107-16. Doi: 10.1212/WNL.0000000000004313. 11. Coles A.J., Cohen J.A., Fox E.J., et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017;89(11):1117-26. Doi: 10.1212/WNL.0000000000004354. 12. Rotondi M., Molteni M., Leporati P., et al. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: An example of selective anti-TSH- receptor immune response. Front Endocrinol (Lausanne). 2017;8:254. Doi: 10.3389/fendo. 2017.00254. 13. Muller I., Moran C., Lecumberri B., et al. 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. Eur Thyroid J. 2019;8(4):173-85. Doi: 10.1159/ 000500881.
Автор для связи: Кристина Юрьевна Жеребчикова, ассистент кафедры эндокринологии № 1 Института клинической медицины им. Н.В. Склифосовского, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет), Москва, Россия; k.y.zherebchikova@gmail.com ORCID:
К.Ю. Жеребчикова (K.Yu. Zhertebchikova), https://orcid.oig/0000-0003-0292-5907
А.С. Ермолаева (A.S. Ermolaeva), https://orcid.org/0000-0002-6471-8252
Ю.П. Сыч (Yu.P. Sych), https://orcid.org/0000-0002-7000-0095
В.В. Фадеев (V.V. Fadeev), https://orcid.org/0000-0002-2504-7468